Suppression of breast cancer metastasis through the inactivation of ADP-ribosylation factor 1

Xiayang Xie, Shou-Ching Tang, Yafei Cai, Wenhu Pi, Libin Deng, Guangyu Wu, Alain Chavanieu, Yong Teng

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Metastasis is the major cause of cancer-related death in breast cancer patients, which is controlled by specific sets of genes. Targeting these genes may provide a means to delay cancer progression and allow local treatment to be more effective. We report for the first time that ADP-ribosylation factor 1 (ARF1) is the most amplified gene in ARF gene family in breast cancer, and high-level amplification of ARF1 is associated with increased mRNA expression and poor outcomes of patients with breast cancer. Knockdown of ARF1 leads to significant suppression of migration and invasion in breast cancer cells. Using the orthotopic xenograft model in NSG mice, we demonstrate that loss of ARF1 expression in breast cancer cells inhibits pulmonary metastasis. The zebrafish-metastasis model confirms that the ARF1 gene depletion suppresses breast cancer cells to metastatic disseminate throughout fish body, indicating that ARF1 is a very compelling target to limit metastasis. ARF1 function largely dependents on its activation and LM11, a cell-active inhibitor that specifically inhibits ARF1 activation through targeting the ARF1-GDP/ARNO complex at the Golgi, significantly impairs metastatic capability of breast cancer cell in zebrafish. These findings underline the importance of ARF1 in promoting metastasis and suggest that LM11 that inhibits ARF1 activation may represent a potential therapeutic approach to prevent or treat breast cancer metastasis.

Original languageEnglish (US)
Pages (from-to)58111-58120
Number of pages10
JournalOncotarget
Volume7
Issue number36
DOIs
StatePublished - Jan 1 2016

Fingerprint

ADP-Ribosylation Factor 1
Breast Neoplasms
Neoplasm Metastasis
Zebrafish
Genes
Gene Targeting
Golgi Apparatus
Heterografts

Keywords

  • ARF1
  • Breast cancer
  • LM11
  • Metastasis
  • Zebrafish

ASJC Scopus subject areas

  • Oncology

Cite this

Suppression of breast cancer metastasis through the inactivation of ADP-ribosylation factor 1. / Xie, Xiayang; Tang, Shou-Ching; Cai, Yafei; Pi, Wenhu; Deng, Libin; Wu, Guangyu; Chavanieu, Alain; Teng, Yong.

In: Oncotarget, Vol. 7, No. 36, 01.01.2016, p. 58111-58120.

Research output: Contribution to journalArticle

Xie, Xiayang ; Tang, Shou-Ching ; Cai, Yafei ; Pi, Wenhu ; Deng, Libin ; Wu, Guangyu ; Chavanieu, Alain ; Teng, Yong. / Suppression of breast cancer metastasis through the inactivation of ADP-ribosylation factor 1. In: Oncotarget. 2016 ; Vol. 7, No. 36. pp. 58111-58120.
@article{62fc4cfcc9ea41df89a6f357038e4ac5,
title = "Suppression of breast cancer metastasis through the inactivation of ADP-ribosylation factor 1",
abstract = "Metastasis is the major cause of cancer-related death in breast cancer patients, which is controlled by specific sets of genes. Targeting these genes may provide a means to delay cancer progression and allow local treatment to be more effective. We report for the first time that ADP-ribosylation factor 1 (ARF1) is the most amplified gene in ARF gene family in breast cancer, and high-level amplification of ARF1 is associated with increased mRNA expression and poor outcomes of patients with breast cancer. Knockdown of ARF1 leads to significant suppression of migration and invasion in breast cancer cells. Using the orthotopic xenograft model in NSG mice, we demonstrate that loss of ARF1 expression in breast cancer cells inhibits pulmonary metastasis. The zebrafish-metastasis model confirms that the ARF1 gene depletion suppresses breast cancer cells to metastatic disseminate throughout fish body, indicating that ARF1 is a very compelling target to limit metastasis. ARF1 function largely dependents on its activation and LM11, a cell-active inhibitor that specifically inhibits ARF1 activation through targeting the ARF1-GDP/ARNO complex at the Golgi, significantly impairs metastatic capability of breast cancer cell in zebrafish. These findings underline the importance of ARF1 in promoting metastasis and suggest that LM11 that inhibits ARF1 activation may represent a potential therapeutic approach to prevent or treat breast cancer metastasis.",
keywords = "ARF1, Breast cancer, LM11, Metastasis, Zebrafish",
author = "Xiayang Xie and Shou-Ching Tang and Yafei Cai and Wenhu Pi and Libin Deng and Guangyu Wu and Alain Chavanieu and Yong Teng",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.11185",
language = "English (US)",
volume = "7",
pages = "58111--58120",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "36",

}

TY - JOUR

T1 - Suppression of breast cancer metastasis through the inactivation of ADP-ribosylation factor 1

AU - Xie, Xiayang

AU - Tang, Shou-Ching

AU - Cai, Yafei

AU - Pi, Wenhu

AU - Deng, Libin

AU - Wu, Guangyu

AU - Chavanieu, Alain

AU - Teng, Yong

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Metastasis is the major cause of cancer-related death in breast cancer patients, which is controlled by specific sets of genes. Targeting these genes may provide a means to delay cancer progression and allow local treatment to be more effective. We report for the first time that ADP-ribosylation factor 1 (ARF1) is the most amplified gene in ARF gene family in breast cancer, and high-level amplification of ARF1 is associated with increased mRNA expression and poor outcomes of patients with breast cancer. Knockdown of ARF1 leads to significant suppression of migration and invasion in breast cancer cells. Using the orthotopic xenograft model in NSG mice, we demonstrate that loss of ARF1 expression in breast cancer cells inhibits pulmonary metastasis. The zebrafish-metastasis model confirms that the ARF1 gene depletion suppresses breast cancer cells to metastatic disseminate throughout fish body, indicating that ARF1 is a very compelling target to limit metastasis. ARF1 function largely dependents on its activation and LM11, a cell-active inhibitor that specifically inhibits ARF1 activation through targeting the ARF1-GDP/ARNO complex at the Golgi, significantly impairs metastatic capability of breast cancer cell in zebrafish. These findings underline the importance of ARF1 in promoting metastasis and suggest that LM11 that inhibits ARF1 activation may represent a potential therapeutic approach to prevent or treat breast cancer metastasis.

AB - Metastasis is the major cause of cancer-related death in breast cancer patients, which is controlled by specific sets of genes. Targeting these genes may provide a means to delay cancer progression and allow local treatment to be more effective. We report for the first time that ADP-ribosylation factor 1 (ARF1) is the most amplified gene in ARF gene family in breast cancer, and high-level amplification of ARF1 is associated with increased mRNA expression and poor outcomes of patients with breast cancer. Knockdown of ARF1 leads to significant suppression of migration and invasion in breast cancer cells. Using the orthotopic xenograft model in NSG mice, we demonstrate that loss of ARF1 expression in breast cancer cells inhibits pulmonary metastasis. The zebrafish-metastasis model confirms that the ARF1 gene depletion suppresses breast cancer cells to metastatic disseminate throughout fish body, indicating that ARF1 is a very compelling target to limit metastasis. ARF1 function largely dependents on its activation and LM11, a cell-active inhibitor that specifically inhibits ARF1 activation through targeting the ARF1-GDP/ARNO complex at the Golgi, significantly impairs metastatic capability of breast cancer cell in zebrafish. These findings underline the importance of ARF1 in promoting metastasis and suggest that LM11 that inhibits ARF1 activation may represent a potential therapeutic approach to prevent or treat breast cancer metastasis.

KW - ARF1

KW - Breast cancer

KW - LM11

KW - Metastasis

KW - Zebrafish

UR - http://www.scopus.com/inward/record.url?scp=84988430449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988430449&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.11185

DO - 10.18632/oncotarget.11185

M3 - Article

VL - 7

SP - 58111

EP - 58120

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 36

ER -